logo.png
GLUCOTRACK ANNOUNCES EARLY ACCURACY DATA FOR ITS IMPLANTABLE CONTINUOUS GLUCOSE MONITOR
January 02, 2024 12:33 ET | GlucoTrack, Inc.
Rutherford, NJ, Jan. 02, 2024 (GLOBE NEWSWIRE) -- GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), a medical device company focused on the design, development, and commercialization...
Vantage Market Research.png
Global Artificial Intelligence (AI) in Drug Discovery Market ($4197.5 Mn by 2028) Growth Forecast at 41.5% CAGR During 2022 to 2028 COVID Impact and Global Analysis by Vantage Market Research
March 03, 2022 04:49 ET | Vantage Market Research
WASHINGTON, March 03, 2022 (GLOBE NEWSWIRE) -- The Global Artificial Intelligence in Drug Discovery Market size is expected to reach USD 4,197.5 Million by 2028, exhibiting a Compound Annual Growth...
P2D Bioscience Awarded NIH Grant to Develop PD2007
June 22, 2011 11:06 ET | P2D Bioscience
CINCINNATI, OH and MUMBAI, INDIA--(Marketwire - Jun 22, 2011) - ...
P2D Bioscience Lead ADHD Drug Demonstrates Efficacy in Preclinical Testing
April 12, 2011 08:00 ET | P2D Bioscience
CINCINNATI, OH and MUMBAI, INDIA--(Marketwire - Apr 12, 2011) - P2D Bioscience (P2D, Inc.), a pharmaceutical development company, today announced that its lead Attention Deficit/Hyperactivity Disorder...